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ORIGINAL RESEARCH
Abstract: Increased attention has been given to the alternatives to stimulants in the treatment
of attention deficit hyperactivity disorder (ADHD) in both adults and children. This short-
term, double-blind trial was designed to evaluate the extended-release form of bupropion in
adult subjects meeting DSM-IV and the Utah Diagnostic Criteria for ADHD. Outcome
measures were the Clinical Global Impressions-Improvement (CGI-I) and the Wender-Reimherr
Adult Attention Deficit Disorder Scale (WRAADDS), which assesses adult ADHD symptoms.
Outcome (defined by the CGI-I, average WRAADDS scores, or a 50% improvement on the
WRAADDS) favored bupropion SR over placebo, but achieved statistical significance on
only one, post hoc measure. Other measures showed trends for improvement with bupropion.
Given the small size of this study, these findings deserve further exploration.
Keywords: bupropion SR, ADHD, adult, controlled study
Introduction
Attention deficit hyperactivity disorder (ADHD) is the most common psychiatric
disorder in childhood, and recent research has documented its persistence into
adulthood (Faraone et al 2000). The stimulant medications methylphenidate and
dextroamphetamine are the most widely accepted and successfully tested treatments
for ADHD in children and adults (Wender et al 1985; Wender 1995; Cyr and Brown
1998; Wender 1998; Wilens and Spencer 2000). However, a number of concerns
including questions of abuse, problems in administration, lack of efficacy in some
patients, and controversies regarding the stimulants have limited the use of these
medications in adults with suspected ADHD. These factors may contribute to an
undertreatment of ADHD in adults. Consequently, there have been efforts to find
alternative nonstimulant treatment approaches for ADHD.
One of the most commonly proposed alternatives has been the antidepressants,
particularly those with noradrenergic activity. There have been multiple reports on
the use of such antidepressants for the treatment of ADHD in both pediatric and
adult populations. These include imipramine (Huessy and Wright 1970; Rapoport et
al 1974), desipramine (Donnelly et al 1986; Biederman et al 1989), nortriptyline
(Spencer et al 1993), venlafaxine (Hedges et al 1995), protriptyline (Wilens et al
1996), and atomoxetine (Spencer et al 1998; Michelson et al 2003).
There have been a number of such reports on bupropion (Wender and Reimherr
1990; Conners et al 1996; Wilens et al 2001). Although the mechanism of action of
bupropion is unknown, it seems to potentiate central nervous system activity of
both norepinephrine and dopamine. It is a weak inhibitor of both dopamine and
norepinephrine reuptake (Richelson 1991), but it may potentiate the activity of
these two neurotransmitters through other, more complex, mechanisms (Ascher et al
1995). Among these antidepressants, only bupropion appears to have this dual
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dopamine–norepinephrine mechanism of action (Golden et
al 1988; Richelson 1991). In this regard, the pharmacologic
activity of bupropion is more similar to the presumed action
of stimulants (Patrick et al 1987; Heal et al 1989). A number
of theories regarding the etiology of ADHD have suggested
that this dual mechanism of action is important in its
treatment (Zametkin and Rapoport 1987; Hechtman 1994).
Despite widespread use of bupropion in the treatment
of ADHD, there are only limited data from controlled studies
regarding its effectiveness. Documenting its efficacy in
ADHD is not only of clinical interest, but might lead to new
avenues of research regarding the etiology of ADHD. In
the past, we have reported on an initial exploratory, open-
label study on the use of bupropion in adult ADHD (Wender
and Reimherr 1990). In this study of 19 adults previously
treated with either stimulants or monoamine oxidase
inhibitors, 14 experienced moderate to marked benefit from
bupropion. Ten of these patients chose to remain on
bupropion rather than their former medication. These results
were in part replicated by a controlled study by Wilens et al
(2001).
The first of these two studies employed the immediate-
release form of bupropion that usually requires three-times-
daily administration. The sustained-release (SR) formulation
of bupropion (used in the second study) is bioequivalent to
the immediate-release formulation. Following multiple-day
administration, the sustained-release formulation of
bupropion produces peak plasma concentrations of
bupropion that are approximately 85% of those achieved
with the immediate-release formulation. In theory, this
should provide fewer peak-related side effects and possibly
a lower risk of seizures (PDR 2001). This alternative form
of bupropion may make the medication more acceptable in
the treatment of ADHD. The sustained-release formulation
is more convenient to use, and Reimherr et al (1998) found
antidepressant efficacy in once-daily dosing.
On the basis of these factors, we conducted a controlled
study of bupropion SR to evaluate its short-term efficacy in
adults with ADHD.
Methods
This study consisted of a 1-week baseline phase with single-
blind placebo administration followed by a 6-week
randomized, double-blind, placebo-controlled, parallel-
design phase. The study was reviewed and approved by the
Institutional Review Board of the University of Utah Health
Sciences Center.
In the double-blind portion, 60% of the patients were
assigned to bupropion SR and 40% to placebo. (This uneven
assignment was done to maximize the number of initial
bupropion SR responders enrolled in a long-term, follow-
up study.) Subjects were recruited from clinic patients,
referrals, and a limited amount of public solicitations. All
subjects received a comprehensive description of the study
and they provided informed consent before enrollment.
Outpatient subjects aged at least 18 years were required to
meet not only DSM-IV but also the more restrictive Utah
Criteria for ADHD in adults (Wender 1995) and to have a
minimum score of 15 on the Wender-Reimherr Adult
Attention Deficit Disorder Scale (WRAADDS).
The Utah Criteria were developed to identify a
homogeneous “core” ADHD population and are quite
restrictive. They involve assessing both childhood and adult
signs and symptoms, preferably using the subjects’ parents
to assess their childhood behavior and a “significant other”
to assess current symptoms. The childhood criteria are a
childhood history consistent with ADHD in childhood as
defined by A or B:
A. Narrow criteria. The individual met DSM-IV criteria
for ADHD in childhood (6 of the 9 signs or symptoms
of inattention and/or 6 of the 9 signs or symptoms of
hyperactivity/impulsivity).
B. Broad criteria. The individual had a history of attention
deficits and hyperactivity, and at least one of the
following: behavior problems in school, impulsivity,
over-excitability, or temper outbursts. The patient also
had a “Parent Rating Scale” or “Wender Utah Rating
Scale” score in the 95th percentile.
The adult criteria are at least moderate impairment of both
motor hyperactivity and attentional difficulties, plus at least
two of the following characteristics: affective lability,
inability to complete tasks/disorganization, hot temper,
emotional overreactivity/stress intolerance, and impulsivity.
The intensity of these symptoms was assessed using the
WRAADDS.
Any history of stimulant drug abuse or other recent
substance abuse would exclude a patient from clinical trials
involving stimulants. The Utah Criteria also exclude patients
with the following characteristics or disorders:
1. bipolar and depressive mood disorders
2. signs and symptoms of schizophrenic spectrum disorders
3. borderline personality disorder
4. antisocial personality disorder.
Subjects were required to have a spouse or close family
member who was willing to attend visits with the patientsNeuropsychiatric Disease and Treatment 2005:1(3) 247
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to report on their symptoms. Information supplied by family
members supplemented the patient’s report and was
incorporated as appropriate in scoring both the WRAADDS
and Clinical Global Impressions-Improvements scale
(CGI-I). This was done in a joint interview. (It is our
experience that the use of a family member significantly
improves the validity and reliability of the assessment of
adult patients with ADHD.) Additionally, subjects had to
have at least moderate impairment in one area of social
adjustment as measured by the Weissman Social Adjustment
Scale (WSAS) (Weissman 1975). In addition to the
exclusion factors in the Utah Criteria, eating disorders,
seizure disorders, history of significant head injury, and
situational stresses that were severe enough to confuse
interpretation of outcome measures were exclusionary
factors. Women who were pregnant or breast feeding,
subjects under custody of the criminal justice system,
subjects with a history of treatment with bupropion, and
subjects at risk for suicide were excluded. Finally,
individuals with other axis I disorders were excluded.
To avoid confounding the antidepressant effects of
bupropion with its putative properties in ADHD, we were
particularly concerned about excluding patients with
significant depressive symptoms. Consequently, patients
scoring over 15 on the Hamilton Depression Scale (HAM-
D), having a score of 8 or more on the sum of HAM-D
items #1, #2, #3, and #7, or meeting DSM-IV criteria for
current major depression or dysthymia were excluded.
However, patients with a history of a single episode of major
depression associated with a significant life stress were
allowed in the study.
The WRAADDS was used to assess symptoms specific
to ADHD. This is a 28-point, clinician-administered, semi-
structured interview containing seven items: attention
difficulties, hyperactivity/restlessness, temper, mood
instability, emotional overreactivity, disorganization, and
impulsivity. The WRAADDS (Reimherr et al 2003) is a
modification of the Targeted Attention Deficit Disorder Scale
(Wender 1995). It is currently available from the authors
and will be published in the near future. The physician-rated
CGI-I scale was used to assess general improvement. To
assess social functioning, the WSAS was administered by a
rater experienced in its use. The WSAS is a clinician-
administered scale addressing overall social adjustment as
well as five specific components: work, social leisure,
extended family, marriage, and parental functioning
(Weissman 1975).
Bupropion SR was initiated at 100 mg/day and titrated
by 100-mg/day increments based on clinical response and
as tolerated to a maximum dose of 400 mg/day (200 mg
twice daily), usually reached after 21 days on study
medication. An attempt was made to increase the dose of
bupropion over the first 3 weeks to the maximum tolerated
dose or until a significant response was produced as assessed
by the CGI-I scale. Dosing was flexible and could be either
once or twice daily, depending upon response, adverse
effects, and patient preference. However, if the total daily
dose exceeded 200 mg, it was divided between two daily
doses. The average daily dose was 298 mg/day at the end of
the study.
Clinic visits were done at days 0, 7, 14, 21, 35, and 49.
After the conclusion of the study, patients were allowed to
enter a 6-month open-label study. At the conclusion of either
portion of the overall study, patients were followed until
stable and then treated as private clinic patients or referred
to an outside clinic.
Patients who had a CGI-I score of 1 or 2 (very much or
much improved) or who had a reduction in the WRAADDS
of 50% or more were categorized as treatment responders.
Fisher’s exact test was used to compare the proportion of
responders on placebo versus bupropion SR. To compare
study groups on continuous variables a repeated measures
ANOVA (using the screening visit and the last double-blind
visit) was performed. For comparison of groups on
continuous variables at specific time intervals, the Mann-
Whitney (Wilcoxon) test was used. All statistical tests were
two-tailed with statistical significance at the p = 0.05 level.
All patients with at least one outcome measure during the
double-blind period were included using a last-visit-carried-
forward design. Statistical tests were performed using the
SPSS 11.5 statistical package.
Results
Fifty-nine patients (43 male, 16 female) signed informed
consent for entry into the study. All but two patients were
assessed as having substantial symptoms in both attentional
and hyperactive areas. These two patients had primarily
attentional symptoms. The patients assigned to two treatment
groups (placebo or bupropion SR) did not differ in
demographic or pretreatment measures (Table 1). There
were mild elevations in anxiety and depression as indicated
by average HAM-D scores of 10.1 ± 4.9 (all scores were
below 15) and average Hamilton Anxiety Scale (HAM-A)
scores of 11.9 ± 5.0. Fourteen patients (24%) scored aboveNeuropsychiatric Disease and Treatment 2005:1(3) 248
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15 on the HAM-A. Seventy-nine percent of patients were
experiencing at least moderate problems in their overall
social adjustment, a non-surprising number given that one
requirement for admission was at least moderate impairment
in one area of social adjustment. Work and marriage were
the most common problem areas.
Of the 59 patients who entered the study, 47 provided
outcome data during the double-blind period. Patients
dropping out either did not complete the single-blind
evaluation or did not furnish outcome data during the double-
blind period following randomization. There were no
significant pretreatment differences between these patients
and those continuing in the study. Furthermore, there was
no evidence of adverse effects leading to study withdrawal.
Data were collected on vital signs and side effects at
each visit. There were no significant adverse effects and the
medication was well tolerated.
Two criteria were used to define response: a 50% or more
reduction in the total WRAADDS score, and ratings of
“much” to “very much” improved on the CGI-I. Table 2
shows the outcome measures for the 47 patients who
completed the double-blind period. Compared with those
receiving placebo, patients on bupropion SR were more
likely to show a 50% improvement in their WRAADDS
scores from the screening visit to the last visit in the double-
blind period (39% versus 11%; p < 0.05, Fisher’s exact test).
Conversely, if improvement was measured from the end of
the single-blind period to last visit, the difference was no
longer significant (32% versus 11%; p = 0.15, Fisher’s exact
test). On the CGI-I, more bupropion SR than placebo
recipients were improved (41% versus 22%; p = 0.15,
Fisher’s exact test), but this difference was not statistically
significant.
There was a decrease in average scores for all seven items
of the WRAADDS. However, both patients on placebo and
those on bupropion SR demonstrated this improvement, and
the difference between the two groups was not significant
on this measure.
Figure 1 shows the total WRAADDS for the double-
blind assessment period for the 18 placebo and 29 bupropion
SR patients. This graph does not carry forward data on
patients who dropped out. Both groups showed lower
WRAADDS scores through the first week of the double-
blind period. Thereafter, the placebo patients showed no
more change, while the bupropion SR patients improved an
additional 3.5 points. The subjects in the active treatment
arm averaged 20.3 at the screening evaluation and this
improved to 12.9 for an average 36% improvement. The
placebo subjects averaged 19.7 at the screening evaluation
and showed a 25% improvement to 14.7. Repeated measures
ANOVA (using only screen and last visit) uncovered a main
effect for time (p < 0.0005) but no drug-by-time interaction
(p < 0.38). The difference between the placebo and bupropion
SR groups on the total WRAADDS scores at the end of the
double-blind period did not achieve statistical significance.
Table 1 Pretreatment demographic and clinical characteristics
of all adults enrolled in the study
Variable Bupropion SR Placebo Total
N3 5 2 4 5 9
Male/female 25/10 18/6 43/16
Age (y) (mean ± SD) 34.3 ± 14.8 34.6 ± 11.2 34.4 ± 13.4
GAF (mean ± SD) 53.3 ± 4.6 54.6 ± 3.1 53.9 ± 4.1
HAM-D (mean ± SD) 10.0 ± 4.7 10.2 ± 5.2 10.1 ± 4.9
HAM-A (mean ± SD) 12.1 ± 5.2 11.5 ± 4.7 11.9 ± 5.0
Parent Rating Scale
(mean ± SD) 19.8 ± 5.5 19.5 ± 5.0 19.6 ± 5.1
Screening WRAADDS
(total) (mean ± SD) 20.3 ± 3.7 20.2 ± 3.7 20.2 ± 3.7
WRAADDS subscales: percentage of patients with at least moderate
impairment
Attention difficulties 100 100 100
Hyperactivity 91 96 93
Temper 77 79 78
Mood instability 89 96 92
Overreactivity 91 88 90
Disorganization 97 100 98
Impulsivity 94 96 95
Weissman Social Adjustment Scale: percentage of patients with at least
moderate impairment
Work 67 60 64
Social leisure 50 45 48
Extended family 39 20 30
Marital 75 47 62
Parental 20 14 17
Overall functioning 83 74 79
Abbreviations: GAF, Global Assessment of Functioning Scale; HAM-A,
Hamilton Anxiety Scale; HAM-D, Hamilton Depression Scale-17 item;
WRAADDS, Wender-Reimherr Adult Attention Deficit Disorder Scale.
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Discussion
Although bupropion SR produced more improvement than
placebo in reducing ADHD symptoms in this short-term,
double-blind study, statistical analysis indicated that these
were nonsignificant numerical trends favoring bupropion
SR. There was, however, a significant post hoc difference
when comparing the percentage of responders defined by a
50% WRAADDS improvement over the screening
evaluation (Table  2), although this represents an
unconventional manner of analysis. No statistically
significant differences were found between bupropion and
placebo a priori. This limited statistical significance stands
in contrast to the more positive studies of bupropion found
in the literature.
Most studies that employ a single-blind placebo phase
use the results at the end of the single-blind period to
measure change over the course of the study. This is done
partly to give researchers an extended opportunity to remove
inappropriate patients. Additionally, it is generally believed
that the single-blind phase may increase the power of the
study. We had initially examined this data set employing
the scores at the end of the single-blind phase to measure
change over the course of the study. However, after
producing a graph of the WRAADDS for the study visits,
and noting the changes during the single-blind week on
placebo, we decided to measure improvement from both
the beginning and the end of the single-blind placebo period.
In contrast to expectations, the single-blind data actually
reduced the differences found in the study.
The difference between medication and placebo
conditions was significant when comparing a 50%
WRAADDS improvement over the screening period but was
not significant when using a CGI-I of “much” or “very
much” improved to define responders. Treatment differences
as measured by the average score on the WRAADDS and
the individual WRAADDS items also failed to achieve
significance.
This limited statistical significance contrasts with
previously reported studies evaluating bupropion in ADHD.
Five factors may account for why these results differ from
those of previous studies.
First, the uneven numbers of subjects randomized to
bupropion SR and placebo in the initial, double-blind portion
of the study reduced the study’s statistical power. If equal
numbers of patients had been placed in both treatment
groups, and if the same response rates were observed, the
results on the CGI-I would have achieved statistical
significance. Second, the small sample size limited the
overall power of the study to detect a difference. Third, it is
possible that a higher dose would have produced greater
differences. A study by Wilens et al (2001), with an average
dose of 362 mg/day compared with our 298 mg/day, found
bupropion SR to be statistically superior to placebo.
However, when the bupropion SR responders in our study
were compared with nonresponders at the end of the double-
blind period, we found that the responders were taking
slightly lower average doses (287 mg/day for responders
versus 306 mg/day for the nonresponders), suggesting that
a higher dose may not necessarily produce a more robust
response. Fourth, given the stricter definition of
improvement (compared with Wilens’ study), it is not
surprising that the study had a lower percentage of
medication responders. However, this study also had a higher
percentage of placebo responders (22%) than other studies.
A review of five controlled adult ADHD studies discovered
a range of placebo responders from 4% (Spencer et al 2001)
to 14% (Wilens et al 1999). The current study had four
placebo responders. Three of these were followed for 4–6
months, and all three continued to do well without
medication.
Finally, and perhaps most significantly, there was a very
important difference between the design of this study and
that of Wilens et al (2001) that might render a direct
comparison misleading. All patients with current major
depression, dysthymia, or symptoms of depression as
measured by the HAM-D were excluded from our study.
The only depressive diagnosis allowed was a single past
Table 2 Outcome values at the end of double-blind treatment
Variable Bupropion SR Placebo p-value
N2 9 1 8
GAF (mean ± SD) 57.5 ± 8.1 56.2 ± 3.6 NS
CGI-I (% much or very
much improved) 41 22 = 0.15
HAM-A (mean ± SD) 10.2 ± 5.4 8.1 ± 4.1 NS
WRAADDS
(mean ± SD) (total) 12.9 ± 5.6 14.7 ± 5.1 NS
50% improvement (%) 39 11 < 0.05
WRAADDS subscales: percentage improvement over screening evaluation
Attention difficulty 26 17 NS
Hyperactivity 28 12 NS
Temper 44 46 NS
Mood instability 41 41 NS
Overreactivity 45 34 NS
Disorganization 29 16 = 0.06
Impulsivity 33 27 NS
Abbreviations: CGI-I, Clinical Global Impressions-Improvement; GAF, Global
Assessment of Functioning; HAM-A, Hamilton Anxiety Scale; NS, not significant;
WRAADDS, Wender-Reimherr Adult Attention Deficit Disorder Scale.Neuropsychiatric Disease and Treatment 2005:1(3) 250
Reimherr et al
episode of major depression that was clearly related to
environmental stresses. Conversely, in Wilens’ study, 20%
of the patients had a current diagnosis of major depression
and 60% had past histories of major depression.
Consequently, the samples of patients in these two studies
may be quite different. It may be that bupropion SR works
better in a depressed than a non-depressed ADHD
population.
An important question in the use of bupropion in ADHD
regards the appropriate duration of a trial in evaluating
whether a patient will respond to the medication. In this
study, responders showed a response within 4 weeks at a
dose of 300 mg/day. There was little additional recruitment
of bupropion responders after week 4. Conversely, in the
Wilens report there were patients who seemed to become
responders between weeks 4 and 6. Despite the fact that no
additional responders were identified between week 4 and
week 6, we would still recommend 6 weeks as the
appropriate duration for short-term double-blind studies with
bupropion.
There is a significant question regarding the level of
improvement in ADHD symptoms required to produce
clinically meaningful improvement in psychiatric
adjustment. Other research groups commonly use a 30%
improvement in ADHD symptoms (using different outcome
measures) to define responders. In contrast, most studies
on depression require a 50% improvement on the HAM-D
to define responders and even higher levels to define
remission. In this study, as in our previous studies, CGI-I
scores of “moderately improved” were associated with
50%–60% improvements in symptoms as measured by the
WRAADDS. Post hoc analyses indicated that our choice of
a 50% improvement rate was as successful as the lower level
in detecting a medication effect in the double-blind period.
Over an extended period greater levels of symptom
improvement could be expected.
In conclusion, bupropion SR was well tolerated in this
study. The twice-daily dosing of bupropion is an advantage
over the often more frequent dosing schedules of traditional
methylphenidate. This study was limited by small sample
size and its unequal distribution of patients. These findings
in conjunction with previous studies suggest that bupropion
SR may have a role in the treatment of adult ADHD as an
alternative to stimulant medication.
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